Table 1. Patient characteristics.
| Patient | Age | Sex | Tumor type1 | IDH-1 (R132H) | Disease Burden2 | Survivin+ Cells in Tumor (%) | Doses of Vaccine | PFS (weeks) |
|---|---|---|---|---|---|---|---|---|
| 1 | 38 | M | G | + | + | 22% | 4 + 14 | 208+ |
| 2 | 58 | M | G | + | + | 1% | 4 + 2 | 88.0 |
| 3 | 57 | M | A | + | + | 2% | 4 + 1 | 96.4 |
| 4 | 45 | F | G | + | +++ | 10% | 4 | 8.0 |
| 5 | 52 | F | G | - | + | 7% | 4 | 8.6 |
| 6 | 48 | F | G | - | ++ | 8% | 4 | 10.4 |
| 7 | 61 | M | G | - | + | 15% | 4 | 25.1 |
| 8 | 54 | M | G | + | + | 4% | 4 | 9.4 |
1G, glioblastoma; A, anaplastic glioma; 2Disease burden measured on MRI at first dosing: (−) no measureable contrast enhancement (C.E.); (+), measureable C.E. < 1 cm3; (++), >1cm3 but ≤ 5 cm3 C.E.; (+++), >5 cm3 C.E.; PFS: progression-free survival.